About Dr. George Huang
Dr. George Huang specializes in obtaining exclusive information from top universities, labs, and venture capital firms about new technologies in the medical sector. He holds a Ph.D. from Johns Hopkins’ School of Medicine, where he worked under a 2003 Nobel Laureate in chemistry. He speaks three languages, has worked for a Canadian bioinformatics firm, and is published in the four best journals of his field.
In 2008, George launched The S&A FDA Report, which uses a proprietary new strategy to find short-term opportunities in the biotech sector with enormous upside potential and limited risk.
Jun 30th, 2008 |
By Dr. George Huang |
Category: Stock Market Investing
Editor’s Note: Investors kill biotech stocks when the Food and Drug Administration (FDA) doesn’t approve a new drug. You can take advantage of Mr. Market’s overreaction and pick up good companies for cheap when this happens, says Dr. George Huang, editor of new Stansberry Research trading service the S&A FDA Report.
Tags: , DSCO, George Huang, investing in biotech
Posted in Stock Market Investing |
No Comments »
May 30th, 2008 |
By Dr. George Huang |
Category: Stock Market Investing
In 2007, the Maryland lottery had a record year. It pulled in more than $1.5 billion of revenue… $50 million went toward running lottery operations, $110 million to retailers, $500 million to the state, and winners collected the remaining $900 million.
Tags: alzheimer drug, Big pharma, biotech, Flurizan, Lundbeck, Myriad Genetics, US stocks
Posted in Stock Market Investing |
No Comments »
Apr 18th, 2008 |
By Dr. George Huang |
Category: International Investing
The Japanese have gone on a shopping spree. In the last six months, two of Japan’s biggest drugmakers in have scooped up two midsized U.S. biotech firms at nothing short of whopping valuations. This international binge bodes well for us biotech investors.
Tags: Big pharma, biotech, Eisai, Japan, Mgi Pharma, Millennium Pharmaceuticals, Takeda Pharmaceuticals
Posted in International Investing |
No Comments »
Apr 11th, 2008 |
By Dr. George Huang |
Category: Stock Market Investing
Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”
Tags: Big pharma, biotech, Dividends, NBIX, Pfizer, US stocks
Posted in Stock Market Investing |
No Comments »
Apr 5th, 2008 |
By Dr. George Huang |
Category: Stock Market Investing
In 2002, Alkermes thought it had a winner on its hands… The small biotech and its Big Pharma partner, Johnson & Johnson, had developed the drug Risperdal Consta to combat schizophrenia. It was a great deal for a while… The market assumed the drug would be approved by the FDA the first time around.
Tags: Alkermes, Biotech Companies, Biotech Sector, Biotech Stocks, Johnson & Johnson, Risperdal Consta, Stock Prices, US stocks
Posted in Stock Market Investing |
No Comments »